Stock Value

NASDAQ:SSRX / Morningstar / 2007 Annual Report / Website

Company

Healthcare / Drugs

China (Serves local market)

Revenue Sources

• Anemia treatment (stimulates production of red blood cells)
• Platelet deficiency treatment (stimulates platelet production)
• Intefen anti-cancer
• Low white blood cell count (due to chemotherapy) treatment (licensed tech. from Liaoning Sunshine)

Long Term Prospects

Unknown

• Is there competition for similar products in China?
• Similar products from foreign producers?

Management

Unknown

Financial Strength

Strong

• No Debt
• 112.6m in cash
• Steady Cash Flow
• $6 net capital/share

Capital Structure

Strong

• No Debt

Dividends & Growth

Fair

• No dividends
• Volatile stock price
• High of 16 in TTM (trailing twelve months)

Bottom Line

• Tons of cash
• No costs
• Small = Volatile